ClinicalTrials.gg
Not yet recruitingNCT07478237PROACTUpdated Nov 9, 2026

The Preventive Risk Outreach And Cascade Testing

An interventional study of Minimally facilitated platform and AI-powered platform in Genetic Predisposition and Family Members, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Stanford University · Not applicable, Interventional, and Screening

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.

Read the detailed description

The overarching goal of this study is to facilitate cascade genetic testing to reduce the burden of cancer in families with hereditary cancer syndromes (HCS). We will evaluate different versions of a point-of-care cascade genetic testing referral service for probands with recently detected pathogenic or likely pathogenic genetic variants.

02

Conditions studied

  • Genetic Predisposition
  • Family Members

Keywords

  • Cascade genetic testing
03

In context

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

This study's planned enrollment of 400 is above the median of 238 across 86 interventional studies indexed under Genetic Predisposition to Disease.

Browse Genetic Predisposition to Disease studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Probands

  1. Age ≥ 18 years old.
  2. Known to carry a pathogenic or likely pathogenic variant in a gene included in the 2024 current Color Health Cancer Panel Test.
  3. Have at least one (1) first- or second-degree relative who is living in the United States and has not yet had germline genetic testing.

Exclusion Criteria - Probands

1. Unable to read and write English or Spanish.

Inclusion Criteria - Relatives

  1. Age ≥ 18 years old.
  2. Resides in the United States.

Exclusion Criteria - Relatives

  1. Completed genetic testing by a clinician within the last 5 years that included the pathogenic or likely pathogenic variant.
  2. Not a first- or second-degree relative of the proband.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    PROACT Platform - Minimally Facilitated Testing

    The Minimally Facilitated testing arm is a simplified version of the PROACT-AI platform, that provides participants with access to low-cost testing only, in addition to standard of care.

    Other: Minimally facilitated platform

  • Experimental
    PROACT Platform - AI

    The AI-powered arm will provide participants access to low-cost testing via an AI-powered platform as well as provide additional features including genetic education, motivational interviewing, family communication, and complete follow-up surveys.

    Other: AI-powered platform

Interventions

  • OtherMinimally facilitated platform

    This group will receive access to low-cost genetic testing via an email link and an access code.

  • OtherAI-powered platform

    This group will receive access to low-cost genetic testing via an AI-powered platform that will also provide genetic education, motivational interviewing, and family communication

06

What researchers measure

Primary outcomes

  1. Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm

    Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm

    Time frame: 6 months

Secondary outcomes

  1. Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm

    Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm

    Time frame: 6 months

  2. Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm

    Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm

    Time frame: 6 months

  3. Proportion of eligible relatives invited by the patient in each study arm

    Proportion of eligible relatives invited by the patient in each study arm

    Time frame: 180 days

  4. Proportion of eligible relatives who join the PROACT program in each study arm

    Proportion of eligible relatives who join the PROACT program in each study arm

    Time frame: 28 days

  5. Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only]

    Proportion of relatives who completed the genetic risk education modules as measured by platform paradata \[PROACT platform-AI Arm Only\]

    Time frame: 180 days

Other outcomes

  1. Assess Relatives' appraisal of their decision making about genetic testing

    Assess Relatives' appraisal of their decision making about genetic testing, as measured by the Decision Quality Scale. The minimum value for the Decision Quality Scale is 7, and the maximum value is 35. A higher score on this scale indicates a better outcome, i.e. a higher score reflects a more positive appraisal of PROACT by relatives regarding their decision-making about genetic testing.

    Time frame: 180 days +/- 90 days

  2. Relatives' confidence in their understanding of hereditary cancer risk

    To compare enrolled relatives' confidence in their understanding of hereditary cancer risk, using interviews.

    Time frame: 180 days +/- 90 days

  3. Compare the proportion of eligible relatives who requested genetic testing in each study arm

    Using survey responses, compare the proportion of eligible relatives who requested genetic testing within 6 months of enrollment in each study arm, as measured by survey responses.

    Time frame: 6 months

  4. Assess Index patients' appraisal of communication with their relatives

    Assess Index patients' appraisal of communication with their relatives, as measured by a modified Patient Assessment of Family Communication Scale. The minimum value of the scale is 10, and the maximum value is 50. A higher score, controlling for baseline, indicates a greater improvement in the patient's assessment of their communication with relatives.

    Time frame: 180 days +/- 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Sep 2029, 30 months later.

Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 30 months is below that.

Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jun 2026 → Mar 2027, primary completion Dec 2029 → Sep 2029 and completion Dec 2029 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Mar 2027was Jun 2026
Primary completionEst.
Sep 2029was Dec 2029
CompletionEst.
Sep 2029was Dec 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Mar 2027
Nov 9, 2026
Primary completion
Dec 2029→Sep 2029
Nov 9, 2026
Study completion
Dec 2029→Sep 2029
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Jun 2026→Mar 2027
    Primary completion Dec 2029→Sep 2029
    Study completion Dec 2029→Sep 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07478237
Responsible party
Jennifer Lee Caswell-Jin (Assistant Professor of Medicine (Oncology), Stanford University) — Principal investigator
First posted
Mar 17, 2026
Start date
Mar 2027 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Sonia Rios-Ventura
Contact
proactprogram@stanford.edu
6507258762
Allison Kurian, MD
principal investigator · Stanford University
Jennifer Lee Caswell-Jin, MD
principal investigator · Stanford University
Steven Katz, MD
principal investigator · University of Michigan
Lawrence An, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion